UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002418
Receipt number R000002962
Scientific Title Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial
Date of disclosure of the study information 2009/09/01
Last modified on 2013/09/02 08:57:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial

Acronym

Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial

Scientific Title

Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial

Scientific Title:Acronym

Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial

Region

Japan


Condition

Condition

Hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To assess the safety of the combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma, and to determine recommended dose of sorafenib and S-1.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I


Assessment

Primary outcomes

Incident of dose-limiting toxicity

Key secondary outcomes

Adverse events
Response rate
Time to progression
Overall survival


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The combination chemotherapy of sorafenib and S-1

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) hepatocellular carcinoma confirmed by dynamic CT or dynamic MRI and AFP or PIVKA-II is over the institutional upper limit, or histologically confirmed hepatocellular carcinoma
2) no indication for transplantation, surgical resection, local ablation or transcatheter arterial embolization.
3) Child-Pugh A
4) >=20 years old
5) ECOG Performance Status 0 or 1
6) oral intake is possible
7) no preceded systemic chemotherapy (excluded adjuvant chemotherapy)
8) more than one measurable disease
9) Adequate baseline organ function:
neutrophil > 1,500/mm3, hemoglobin >=10.0g/dl, platelets > 75,000/mm3, serum bilirubin <=1.5 times of the institutional upper limit, aspartate aminotransferase and alanine aminotransferase <=5 times of the institutional upper limit, serum creatinine <1.5 mg/dL and creatinin clearance >=50ml/min
10) life expectancy >=12 weeks
11) written informed consent

Key exclusion criteria

1) histrogically confirmed combined type hepatocellular carcinoma or sarcomatous change
2) previous therapy for hepatocellular carcinoma within 30 days
3) preceded chemotherapy used sorafenib or 5-FU (excluded transcatheter arterial embolization or adjuvant chemotherapy)
4) inadequate for administration of sorafenib or S-1
5) active double cancer
6) active infection (excluded viral hepatitis)
7) water diarrhea
8) severe complication
9) refractory ascites of pleural effusion
10) metastases to central nervous system
11) pregnancy or lactaing females
12) inappropriate for entry onto this study in the judgment of the investigator

Target sample size

21


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Kaneko

Organization

Kanazawa University Hospital

Division name

Department of Gastroenterology

Zip code


Address

13-1 Takara-Machi, Kanazawa, Ishikawa

TEL

076-265-2233

Email



Public contact

Name of contact person

1st name
Middle name
Last name Tatsuya Yamashita

Organization

Kanazawa University Hospital

Division name

Department of Gastroenterology

Zip code


Address

13-1 Takara-machi, Kanazawa, Ishikawa

TEL

076-265-2861

Homepage URL


Email

ytatsuya@m-kanazawa.jp


Sponsor or person

Institute

Kanazawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

金沢大学病院(石川県)


Other administrative information

Date of disclosure of the study information

2009 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 08 Month 31 Day

Date of IRB


Anticipated trial start date

2009 Year 10 Month 01 Day

Last follow-up date

2012 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 08 Month 31 Day

Last modified on

2013 Year 09 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002962


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name